Ipratropium Bromide 250mcg/1ml & 500mcg/2ml Nebuliser Solution PIL - UK

Ipratropium Bromide 250 micrograms/1ml Nebuliser Solution
Ipratropium Bromide 500 micrograms/2ml Nebuliser Solution

In this leaflet:

1. What Ipratropium Bromide nebuliser solution is and what it is used for.
2. Before you take Ipratropium Bromide Nebuliser Solution.
3. How to take Ipratropium Bromide Nebuliser Solution.
4. Possible side effects.
5. What to do if you think you have had too much.
6. Reporting of side effects.

1. WHAT IPRATROPION BROMIDE NEBULISER SOLUTION IS AND WHAT IT IS USED FOR

This medicine belongs to a group of medicines called "anticholinergics" which helps to open up the air passages in your lungs so that you can breathe more easily.

This medicine helps to make breathing easier in adults with asthma and chronic obstructive pulmonary disease (COPD). Ipratropium Bromide Nebuliser Solution can be used at the same time as medicines called inhaled bronchodilators (relievers), for example salbutamol.

2. BEFORE YOU TAKE IPRATROPON BROMIDE NEBULISER SOLUTION

Do not take Ipratropium Bromide Nebuliser Solution:

- If you are allergic (hypersensitive) to the active substance Ipratropium Bromide or to any of the other ingredients of Ipratropium Bromide Nebuliser Solution (these are listed in Section 4 - Further Information).

Take special care with Ipratropium Bromide Nebuliser Solution:

- If you have glaucoma (open angle glaucoma).
- If you have a history of prostate problems or bladder outflow obstruction.

Tell your doctor or pharmacist if you:

- Have any medical conditions, especially heart disease, diabetes, or peptic ulcer;
- Are taking any other medicines, including those bought without prescription;
- Are pregnant or planning to become pregnant;
- Are breast-feeding or planning to breast-feed;
- Have any other medical condition or illness.

Driving and using machines:

- Ipratropium Bromide Nebuliser Solution has no known effects on the ability to drive and use machines.

3. HOW TO TAKE IPRATROPON BROMIDE NEBULISER SOLUTION

Aerosol inhaler: Ipratropium Bromide nebuliser solution may be used by children aged 7 years and older.

General instructions:

- Read the leaflet carefully before you start using the medicine and save it for future reference.

4. POSSIBLE SIDE EFFECTS

Most patients experience side effects while using Ipratropium Bromide nebuliser solution, but these side effects are usually mild.

- Dizziness
- Headache
- Hypersensitivity reaction due to the nebuliser solution itself

If any of the side effects get worse or you experience any other side effects not listed in this leaflet, please tell your doctor or pharmacist.

Contact your doctor immediately if:

- You are not getting relief from your current dose.
- Your breathing is getting worse.
- Your chest feels tight.

If you think you have taken too much Ipratropium Bromide Nebuliser Solution:

- Immediately call your doctor or local emergency service.

5. REPORTING OF SIDE EFFECTS

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard

By reporting side effects you can help provide more information on the safety of this medicine.

6. FURTHER INFORMATION

What Ipratropium Bromide Nebuliser Solution contains:

- The active ingredient is Ipratropium Bromide 250 micrograms/mL & 500 micrograms/mL.
- The other ingredients are sodium chloride, water for injection and hydrochloric acid.

What Ipratropium Bromide Nebuliser Solution looks like and contents of the pack:

Ipratropium Bromide Nebuliser Solution is available in 3ml and 6ml cartons for adults and children aged 7 years and over. The cartons contain two 3ml or six 6ml plastic ampoules.

Marketing Authorisation Holder:

Aventis Healthcare Limited, Sage House, 319 Pinner Road, North Harrow, Middlesex, HA1 4HF, United Kingdom.

Manufacturing:

Laboratoire Unither, Espace Industriel Nord, 151 rue André Durouchez - CS 28028, 80084 AMIENS CEDEX 2, France.

This leaflet was last revised in January 2018.

BBBA0952